Cargando…

Receptor for Advanced Glycation End Products and its Inflammatory Ligands are Upregulated in Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis (ALS) is a fatal motor neuron disorder of largely unknown pathogenesis. Recent studies suggest that enhanced oxidative stress and neuroinflammation contribute to the progression of the disease. Mounting evidence implicates the receptor for advanced glycation end-product...

Descripción completa

Detalles Bibliográficos
Autores principales: Juranek, Judyta K., Daffu, Gurdip K., Wojtkiewicz, Joanna, Lacomis, David, Kofler, Julia, Schmidt, Ann Marie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4686801/
https://www.ncbi.nlm.nih.gov/pubmed/26733811
http://dx.doi.org/10.3389/fncel.2015.00485
_version_ 1782406501224153088
author Juranek, Judyta K.
Daffu, Gurdip K.
Wojtkiewicz, Joanna
Lacomis, David
Kofler, Julia
Schmidt, Ann Marie
author_facet Juranek, Judyta K.
Daffu, Gurdip K.
Wojtkiewicz, Joanna
Lacomis, David
Kofler, Julia
Schmidt, Ann Marie
author_sort Juranek, Judyta K.
collection PubMed
description Amyotrophic lateral sclerosis (ALS) is a fatal motor neuron disorder of largely unknown pathogenesis. Recent studies suggest that enhanced oxidative stress and neuroinflammation contribute to the progression of the disease. Mounting evidence implicates the receptor for advanced glycation end-products (RAGE) as a significant contributor to the pathogenesis of certain neurodegenerative diseases and chronic conditions. It is hypothesized that detrimental actions of RAGE are triggered upon binding to its ligands, such as AGEs (advanced glycation end products), S100/calgranulin family members, and High Mobility Group Box-1 (HMGB1) proteins. Here, we examined the expression of RAGE and its ligands in human ALS spinal cord. Tissue samples from age-matched human control and ALS spinal cords were tested for the expression of RAGE, carboxymethyllysine (CML) AGE, S100B, and HMGB1, and intensity of the immunofluorescent and immunoblotting signals was assessed. We found that the expression of both RAGE and its ligands was significantly increased in the spinal cords of ALS patients versus age-matched control subjects. Our study is the first report describing co-expression of both RAGE and its ligands in human ALS spinal cords. These findings suggest that further probing of RAGE as a mechanism of neurodegeneration in human ALS is rational.
format Online
Article
Text
id pubmed-4686801
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-46868012016-01-05 Receptor for Advanced Glycation End Products and its Inflammatory Ligands are Upregulated in Amyotrophic Lateral Sclerosis Juranek, Judyta K. Daffu, Gurdip K. Wojtkiewicz, Joanna Lacomis, David Kofler, Julia Schmidt, Ann Marie Front Cell Neurosci Neuroscience Amyotrophic lateral sclerosis (ALS) is a fatal motor neuron disorder of largely unknown pathogenesis. Recent studies suggest that enhanced oxidative stress and neuroinflammation contribute to the progression of the disease. Mounting evidence implicates the receptor for advanced glycation end-products (RAGE) as a significant contributor to the pathogenesis of certain neurodegenerative diseases and chronic conditions. It is hypothesized that detrimental actions of RAGE are triggered upon binding to its ligands, such as AGEs (advanced glycation end products), S100/calgranulin family members, and High Mobility Group Box-1 (HMGB1) proteins. Here, we examined the expression of RAGE and its ligands in human ALS spinal cord. Tissue samples from age-matched human control and ALS spinal cords were tested for the expression of RAGE, carboxymethyllysine (CML) AGE, S100B, and HMGB1, and intensity of the immunofluorescent and immunoblotting signals was assessed. We found that the expression of both RAGE and its ligands was significantly increased in the spinal cords of ALS patients versus age-matched control subjects. Our study is the first report describing co-expression of both RAGE and its ligands in human ALS spinal cords. These findings suggest that further probing of RAGE as a mechanism of neurodegeneration in human ALS is rational. Frontiers Media S.A. 2015-12-22 /pmc/articles/PMC4686801/ /pubmed/26733811 http://dx.doi.org/10.3389/fncel.2015.00485 Text en Copyright © 2015 Juranek, Daffu, Wojtkiewicz, Lacomis, Kofler and Schmidt. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Juranek, Judyta K.
Daffu, Gurdip K.
Wojtkiewicz, Joanna
Lacomis, David
Kofler, Julia
Schmidt, Ann Marie
Receptor for Advanced Glycation End Products and its Inflammatory Ligands are Upregulated in Amyotrophic Lateral Sclerosis
title Receptor for Advanced Glycation End Products and its Inflammatory Ligands are Upregulated in Amyotrophic Lateral Sclerosis
title_full Receptor for Advanced Glycation End Products and its Inflammatory Ligands are Upregulated in Amyotrophic Lateral Sclerosis
title_fullStr Receptor for Advanced Glycation End Products and its Inflammatory Ligands are Upregulated in Amyotrophic Lateral Sclerosis
title_full_unstemmed Receptor for Advanced Glycation End Products and its Inflammatory Ligands are Upregulated in Amyotrophic Lateral Sclerosis
title_short Receptor for Advanced Glycation End Products and its Inflammatory Ligands are Upregulated in Amyotrophic Lateral Sclerosis
title_sort receptor for advanced glycation end products and its inflammatory ligands are upregulated in amyotrophic lateral sclerosis
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4686801/
https://www.ncbi.nlm.nih.gov/pubmed/26733811
http://dx.doi.org/10.3389/fncel.2015.00485
work_keys_str_mv AT juranekjudytak receptorforadvancedglycationendproductsanditsinflammatoryligandsareupregulatedinamyotrophiclateralsclerosis
AT daffugurdipk receptorforadvancedglycationendproductsanditsinflammatoryligandsareupregulatedinamyotrophiclateralsclerosis
AT wojtkiewiczjoanna receptorforadvancedglycationendproductsanditsinflammatoryligandsareupregulatedinamyotrophiclateralsclerosis
AT lacomisdavid receptorforadvancedglycationendproductsanditsinflammatoryligandsareupregulatedinamyotrophiclateralsclerosis
AT koflerjulia receptorforadvancedglycationendproductsanditsinflammatoryligandsareupregulatedinamyotrophiclateralsclerosis
AT schmidtannmarie receptorforadvancedglycationendproductsanditsinflammatoryligandsareupregulatedinamyotrophiclateralsclerosis